Abstract
Over three years following the discovery of the TAL code, artificial TAL effector DNA binding domains have emerged as the premier platform for building site-specific DNA binding polypeptides for use in biological research. Here, we provide an overview of TAL effector and alternative modular DNA binding domain (mDBD) technologies, focusing on their use in established and emerging architectures for building site-specific endonucleases for genome engineering applications. We also discuss considerations for choosing TAL effector/mDBD or alternative nuclease technologies for genome engineering projects ranging from basic laboratory gene editing of cultured cell lines to therapeutics. Finally, we highlight how the rapid pace of development of mDBD-based, such as monomeric TALENs (I-TevI-TAL), and more recently RNA-guided nucleases (CRISPR-Cas9) has led to a transition in the field of genome engineering towards development of the next generation of technologies aimed at controlling events that occur after targeted DNA breaks are made.
Keywords: DNA repair, double strand break, exonuclease, genome engineering, homing endonuclease, meganuclease, nuclease, TALEN, ZFN, zinc finger nuclease.
Current Gene Therapy
Title:Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies
Volume: 13 Issue: 4
Author(s): Andrew M. Scharenberg, Philippe Duchateau and Julianne Smith
Affiliation:
Keywords: DNA repair, double strand break, exonuclease, genome engineering, homing endonuclease, meganuclease, nuclease, TALEN, ZFN, zinc finger nuclease.
Abstract: Over three years following the discovery of the TAL code, artificial TAL effector DNA binding domains have emerged as the premier platform for building site-specific DNA binding polypeptides for use in biological research. Here, we provide an overview of TAL effector and alternative modular DNA binding domain (mDBD) technologies, focusing on their use in established and emerging architectures for building site-specific endonucleases for genome engineering applications. We also discuss considerations for choosing TAL effector/mDBD or alternative nuclease technologies for genome engineering projects ranging from basic laboratory gene editing of cultured cell lines to therapeutics. Finally, we highlight how the rapid pace of development of mDBD-based, such as monomeric TALENs (I-TevI-TAL), and more recently RNA-guided nucleases (CRISPR-Cas9) has led to a transition in the field of genome engineering towards development of the next generation of technologies aimed at controlling events that occur after targeted DNA breaks are made.
Export Options
About this article
Cite this article as:
Scharenberg M. Andrew, Duchateau Philippe and Smith Julianne, Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies, Current Gene Therapy 2013; 13 (4) . https://dx.doi.org/10.2174/15665232113139990026
DOI https://dx.doi.org/10.2174/15665232113139990026 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes
Current Drug Targets Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry N-Heterocyclic Dronic Acids: Applications and Synthesis
Mini-Reviews in Medicinal Chemistry Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Genetics of Primary CoQ10 Deficiency
Current Genomics Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids
Medicinal Chemistry Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology Identification and Usage of Fluorescent Probes as Nanoparticle Contrast Agents in Detecting Cancer
Current Pharmaceutical Design Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Modern Treatments for Gliomas Improve Outcome
Current Cancer Therapy Reviews Editorial [Hot Topic:Treatment of Neuroblastoma: From Cellular to Molecular Therapy (Executive Editor: Gian Paolo Tonini)]
Current Pharmaceutical Design Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy
Letters in Drug Design & Discovery An Evidence-Based Systematic Review of Stevia by the Natural Standard Research Collaboration
Cardiovascular & Hematological Agents in Medicinal Chemistry Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Assessment and Management of the Adnexal Mass in the Pediatric Population
Current Women`s Health Reviews